← Back to Clinical Trials
Recruiting NCT07382141

Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Cardiotoxicity
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Type INTERVENTIONAL
Phase N/A
Enrollment 400
Sex ALL
Min Age 0 Years
Max Age 18 Years
Start Date 2025-03-17
Completion 2028-12-31
Interventions
Parameters of vascular stiffness

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer survivors a more sensitive and earlier identification of cardiovascular damage resulting from antineoplastic therapy that develops either acutely or remotely after completion of antineoplastic therapy.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of oncological pathology and need for antineoplastic treatment Exclusion Criteria: * None

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE CARDIOTOXICITY TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}